<PAGE>
Exh. 10.5
Amendment No. 1 to Development Agreement
This Amendment No. 1, dated as of July 15, 2004, by and between
Omrix
Biopharmaceuticals, Inc., a corporation organized under the laws of
Delaware
(hereinafter referred to as "Omrix"), and Ethicon, Inc., a
corporation organized
under the laws of New Jersey, acting by and through its Johnson
& Johnson Wound
Management division (hereinafter referred to as "Ethicon," together
with Omrix,
the "Parties" and each individually a "Party"), amends that certain
Development
Agreement. dated as of September 22, 2003 (as amended, the
"Development
Agreement"), by and between the Parties. Capitalized terms which
are used herein
but not defined herein, shall have the meaning assigned to such in
the
Development Agreement.
WHEREAS, the Parties are executing on the date of this amendment an
Amendment
No. 1 to the Supply Agreement to, among other things, expand, in
accordance with
the terms and conditions of Section 2.8(b) of the Supply Agreement,
the FS2
Territory.
NOW THEREFORE, in consideration of the mutual covenants and
consideration set
forth herein, the Parties here
